# MB-105

Source: https://onco.cc/drugs/mb-105/  
OnCo record `mb-105` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MB-105 is an experimental autologous CAR T-cell therapy from March Biosciences, in phase 2 trials for CD5-positive T-cell lymphoma and T-cell acute lymphoblastic leukaemia.

## Summary

MB-105 (CD5.CAR/28zeta CAR T cells (Baylor phase 1, name used in NCT03081910)) is an autologous CAR T-cell therapy from March Biosciences, with Baylor College of Medicine as partner. Autologous T cells engineered to express a CD5-directed chimeric antigen receptor; the company says its CAR design resists the CAR T cells killing each other during manufacture without extra gene editing. Its furthest stage is phase 2, for CD5-positive T-cell lymphoma and T-cell acute lymphoblastic leukaemia. ClinicalTrials.gov registers it in 2 studies linked below. Registry NCT06534060 phase 2 recruiting; long-term follow-up NCT07340814 not yet recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: CD5.CAR/28zeta CAR T cells (Baylor phase 1, name used in NCT03081910)
- Tags: pipeline; ctgov-ingest
- Code: MB-105
- Modality: Autologous CAR T-cell therapy
- Mechanism: Autologous T cells engineered to express a CD5-directed chimeric antigen receptor; the company says its CAR design resists the CAR T cells killing each other during manufacture without extra gene editing.

## Sources

- March Biosciences: march.bio: https://march.bio/mb-105/
- March Biosciences: march.bio: https://march.bio/mb-105/
- March Biosciences: march.bio: https://march.bio/pipeline/
- March Biosciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06534060
- ClinicalTrials.gov: trials of MB-105: https://clinicaltrials.gov/search?intr=MB-105

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [March Biosciences](https://onco.cc/companies/march-biosciences/)
- trials: [A Long-term Follow-up Study of Patients Who Received MB-105](https://onco.cc/trials/nct07340814/), [MB-105 in Patients With CD5 Positive T-cell Lymphoma](https://onco.cc/trials/nct06534060/)

---
JSON: https://onco.cc/api/v1/entities/mb-105.json